03:45 PM EST - Theralase Technologies Inc. : Announced today that it has been granted a U.S. patent for its lead anti-cancer drug, TLD-1433, by the United States Patent and Trademark Office. The US patent provides patent protection for Theralase’s second major platform of anti-cancer PDCs for 20 years from date of filing. Theralase Technologies Inc.
shares V.TLT are trading down $0.005 at $0.37.
